Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohort study.
epidemiology
incidence
overall survival
pancreatic cancer
venous thromboembolism
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
06
05
2024
received:
23
01
2024
accepted:
04
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
Pancreatic cancer (PC) is associated with a high risk of venous thromboembolic events (VTEs). We investigated the incidence of VTE before and after the diagnosis of PC and its association with overall survival. We identified PC patients diagnosed in 2013-2016 from the Finnish Cancer Registry. Data on healthcare visits and death were collected, along with follow-up data through the end of 2020. We compared patients who underwent radical-intent surgery (RIS) to those who underwent palliative treatment (PT) alone. We identified 4086 PC patients, of whom 343 (8.4%) underwent RIS and 3743 (91.6%) received PT. VTE incidence within 1 year before a PC diagnosis was higher in the PT (4.2%, n = 156) than in the RIS group (0.6%, n = 2; p < 0.001). The cumulative incidence of VTE at 12 and 24 months after a PC diagnosis was 6% (n = 21) and 9% (n = 31), respectively, within the RIS group, and 8% (n = 286) and 8% (n = 304) within the PT group. In the PT group, a VTE within 1 year before a PC diagnosis was independently associated with a worse survival {hazard ratio, HR 1.9 [95% confidence interval (CI) 1.6-2.2]}. In both groups, VTE after a PC diagnosis was associated with a worse survival [RIS group: HR 2.6 (95%CI 1.8-3.7) vs. PT group: HR 2.2 (95%CI 1.9-2.4)]. A VTE within 1 year before a PC diagnosis more often occurred among PT PC patients than among patients who underwent RIS. VTE might serve as a diagnostic clue to detect PC at an earlier stage.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70014Informations de copyright
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
Références
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49. doi:10.3322/caac.21820
Frere C, Bournet B, Gourgou S, et al. Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology. 2020;158(5):1346. doi:10.1053/j.gastro.2019.12.009
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy‐associated thrombosis. Blood. 2008;111(10):4902‐4907. doi:10.1182/blood-2007-10-116,327
Giustozzi M, Curcio A, Weijs B, et al. Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost. 2020;120(5):847‐856. doi:10.1055/s-0040-1,709,527
Lee JC, Ro YS, Cho J, et al. Characteristics of venous thromboembolism in pancreatic adenocarcinoma in East Asian ethnics. Medicine. 2016;95(17):1‐8. doi:10.1097/MD.0000000000003472
Okusaka T, Saiura A, Shimada K, Ikeda M, Ioka T, Kimura T. Incidence and risk factors for venous thromboembolism in the cancer—VTE registry pancreatic cancer subcohort. J Gastroenterol. 2023;58(12):1261‐1271. doi:10.1007/s00535-023-02033-3
Yamai T, Ikezawa K, Hiraga E, et al. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first‐line chemotherapy with gemcitabine plus nab‐paclitaxel. PLoS One. 2022;17(3):e0264653. doi:10.1371/journal.pone.0264653
Blom JW, Vanderschoot JPM, Oostindiër MJ, Osanto S, Van Der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529‐535. doi:10.1111/j.1538-7836.2006.01804.x
Berger AK, Singh HM, Werft W, et al. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: a retrospective cohort study. Pancreatology. 2017;17(4):629‐634. doi:10.1016/j.pan.2017.04.012
Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta‐analysis of randomized controlled trials. Blood Coagul Fibrinolysis. 2016;27(3):270‐274. doi:10.1097/MBC.0000000000000413
Peippo MH, Kurki S, Lassila R, Carpén OM. Real‐world features associated with cancer‐related venous thromboembolic events. ESMO Open. 2018;3(5):1‐10. doi:10.1136/esmoopen-2018-000363
Kim JS, Kang EJ, Kim DS, et al. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study. BMC Cancer. 2018;18(1):1‐10. doi:10.1186/s12885-018-5154-3
Larsen AC, Brøndum Frøkjær J, Wishwanath Iyer V, et al. Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors. J Thromb Haemost. 2015;13(4):555‐562. doi:10.1111/jth.12843
Afzal A, Suhong L, Gage BF, et al. Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. Thromb Res. 2020;185:125‐131. doi:10.1016/j.thromres.2019.11.023
Su K, Duan R, Wu Y. Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta‐analysis. Front Oncol. 2024;14:1331706. doi:10.3389/fonc.2024.1331706
White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005;165(15):1782‐1787. doi:10.1001/archinte.165.15.1782
Hettiarachchi RJ, Lok J, Prins MH, Büller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83(1):180‐185.
Felix G, Ferreira E, Ribeiro A, et al. Predictors of cancer in patients with acute pulmonary embolism. Thromb Res. 2023;230:11‐17. doi:10.1016/j.thromres.2023.08.005
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3‐14. doi:10.1007/s11239-015-1311-6
Quan H, Sundararajan V, Halfon P, Fong A. Coding algorithms for defining comorbidities in ICD‐9‐CM and ICD‐10 administrative data. Med Care. 2005;43(11):1130‐1139. doi:10.1097/01.mlr.0000182534.19832.83.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373‐383. doi:10.1016/0021-9681(87)90171-8
Therneau TM. A Package for Survival Analysis in R. 2023. https://cran.r‐project.org/package=survival
Wang J, Kim YD, Kim CH. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin Proc. 2021;96(3):592‐600. doi:10.1016/j.mayocp.2020.05.045
Riedl JM, Schwarzenbacher E, Moik F, et al. Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first‐line chemotherapy with FOLFIRINOX or gemcitabine/nab‐paclitaxel. Thromb Haemost. 2022;122(4):633‐645. doi:10.1055/a-1548-4847
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25‐year population‐based study. Arch Intern Med. 1998;158(6):585‐593. doi:10.1001/archinte.158.6.585
Frere C. Burden of venous thromboembolism in patients with pancreatic cancer. World J Gastroenterol. 2021;27(19):2325‐2340. doi:10.3748/wjg.v27.i19.2325
Lacny S, Wilson T, Clement F, et al. Kaplan–Meier survival analysis overestimates cumulative incidence of health‐related events in competing risk settings: a meta‐analysis. J Clin Epidemiol. 2018;93:25‐35. doi:10.1016/j.jclinepi.2017.10.006
Chiasakul T, Patell R, Maraveyas A, Carrier M, Zwicker JI. Discordant reporting of VTE in pancreatic cancer: a systematic review and meta‐analysis of thromboprophylaxis versus chemotherapeutic trials. J Thromb Haemost. 2021;19(2):489‐501. doi:10.1111/JTH.15175
Lavikainen LI, Guyatt GH, Sallinen VJ, et al. Systematic reviews and meta‐analyses of the procedure‐specific risks of thrombosis and bleeding in general abdominal, colorectal, upper‐gastrointestinal and hepatopancreatobiliary surgery. 2024;279(2):213‐225. doi:10.1097/sla.0000000000006059
Majmudar K, Quintero LD, Fuentes HE, et al. Postoperative venous thromboembolism and mortality in patients with pancreatic surgery. J Surg Oncol. 2019;120(3):494‐500. doi:10.1002/jso.25589
Krepline AN, Christians KK, George B, et al. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer—is it indicated? J Surg Oncol. 2016;114(5):581‐586. doi:10.1002/jso.24361
Eurola A, Mustonen H, Mattila N, Lassila R, Haglund C, Seppänen H. Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. Cancer Med. 2022;11(7):1605‐1616. doi:10.1002/cam4.4397
Mandalà M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007;18(10):1660‐1665. doi:10.1093/annonc/mdm284
Illés D, Ivány E, Holzinger G, et al. New onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES trial): protocol of a prospective, multicentre observational trial. BMJ Open. 2020;10:e037267. doi:10.1136/bmjopen-2020-037267
Takikawa T, Kikuta K, Kume K, et al. New‐onset or exacerbation of diabetes mellitus is a clue to the early diagnosis of pancreatic cancer. Tohoku J Exp Med. 2020;252(4):353‐364. doi:10.1620/tjem.252.353.Correspondence
Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population‐based study. Gastroenterology. 2005;129(2):504‐511. doi:10.1016/j.gastro.2005.05.007
Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to determine risk of pancreatic cancer in patients with new‐onset diabetes. Gastroenterology. 2018;155(3):730‐739.e3. doi:10.1053/j.gastro.2018.05.023
Mattila N, Hisada Y, Przybyla B, et al. Levels of the cancer biomarker CA 19–9 are associated with thrombin generation in plasma from treatment‐naïve pancreatic cancer patients. Thromb Res. 2021;199(December 2020):21‐31. doi:10.1016/j.thromres.2020.12.018
Hisada Y, Mackman N. Cancer‐associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499‐1506. doi:10.1182/blood-2017-03-743,211
Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RCN. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg. 1995;82(8):1101‐1104. doi:10.1002/bjs.1800820831
Moik F, Prager G, Thaler J, et al. Hemostatic biomarkers and venous thromboembolism are associated with mortality and response to chemotherapy in patients with pancreatic cancer. Arterioscler Thromb Vasc Biol. 2021;41(11):2837‐2847. doi:10.1161/ATVBAHA.121.316463
Peippo MH, Kurki S, Seppänen H, Lassila R, Carpén O. CA 19–9 doubling time in pancreatic cancer as a predictor of venous thromboembolism: a hospital database study. Acta Oncol. 2020;59(2):237‐241. doi:10.1080/0284186X.2019.1679881
Bharthuar A, Khorana AA, Hutson A, et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013;132(2):180‐184. doi:10.1016/j.thromres.2013.06.026
Sund R. Quality of the finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505‐515. doi:10.1177/1403494812456637
Pylväläinen J, Talala K, Murtola T, et al. Charlson Comorbidity Index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time. Clin Epidemiol. 2019;11:923‐932. doi:10.2147/CLEP.S218697